Asia-Pacific Graves’ disease Market Size, Share & Trends Analysis Report by Diagnosis (Ultrasound, Imaging Tests, Radioactive Iodine Uptake, and Blood Sample), by Treatment (Anti- Thyroid Medication, Radioactive Iodine Therapy, and Surgery) Forecast Period 2019-2025.
Asia-Pacific Graves’ diseases market is growing at a CAGR of around 5.5% during the forecast period. The region has a potential market for the Grave’s disease market due to the increasing prevalence of diabetes in the emerging economies of the region, especially in China. Diabetic patients, in particular, type-1 diabetic patients, are more prone to develop Grave’s disease. Furthermore, emerging healthcare infrastructure coupled with increasing disposable income is also expected to drive the adoption of treatment of Grave’s disease, in turn affecting the Asia-Pacific Graves’ disease market growth.
According to IDF, in 2017, there were around 1.1, 3.6, and 10.3 million numbers of people, who were diagnosed with diabetes, in Australia, South Korea, and Indonesia respectively. These figures are expected to reach around 1.5, 4.6, and 16.2 million, by 2040, in Australia, South Korea, and Indonesia respectively. The prevalence rate of diabetes in Australia and Indonesia are around 5.1% and 6.3% which increases the probability of person acquiring Grave’s disease and thus, promises the significant market for the Grave’s disease in the region. Whereas, China accounts for nearly 121 million individuals live with diabetes and around 74 million people living with diabetes in India. The development of personalized medicines such as the introduction of traditional Chinese medicine (TCM) further propels the growth of the Asia-Pacific Graves’ disease market during the forecast period.
Despite an economic slowdown in several countries of the region such as India, the increasing public healthcare programs including the increasing private wealth are further expected to propel the healthcare spending of Asia-Pacific by an annual average of 6.6% from 2015 to 2019. Asia-Pacific is growing at a modest rate in the market due to various factors such as rising healthcare spending, improving infrastructure, and rising standards of living. China, India, Japan, Australia, Korea, and Taiwan are the key countries growing at a significant rate in the Asia-Pacific Graves’ diseases market.
Research Methodology:
The market study of the Asia-Pacific Graves’ disease market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Asia-Pacific Graves’ Disease Market Research and Analysis by Diagnosis
2. Asia-Pacific Graves’ Disease Market Research and Analysis by Treatment
The Report Covers:
Asia-Pacific Graves’ diseases market is growing at a CAGR of around 5.5% during the forecast period. The region has a potential market for the Grave’s disease market due to the increasing prevalence of diabetes in the emerging economies of the region, especially in China. Diabetic patients, in particular, type-1 diabetic patients, are more prone to develop Grave’s disease. Furthermore, emerging healthcare infrastructure coupled with increasing disposable income is also expected to drive the adoption of treatment of Grave’s disease, in turn affecting the Asia-Pacific Graves’ disease market growth.
According to IDF, in 2017, there were around 1.1, 3.6, and 10.3 million numbers of people, who were diagnosed with diabetes, in Australia, South Korea, and Indonesia respectively. These figures are expected to reach around 1.5, 4.6, and 16.2 million, by 2040, in Australia, South Korea, and Indonesia respectively. The prevalence rate of diabetes in Australia and Indonesia are around 5.1% and 6.3% which increases the probability of person acquiring Grave’s disease and thus, promises the significant market for the Grave’s disease in the region. Whereas, China accounts for nearly 121 million individuals live with diabetes and around 74 million people living with diabetes in India. The development of personalized medicines such as the introduction of traditional Chinese medicine (TCM) further propels the growth of the Asia-Pacific Graves’ disease market during the forecast period.
Despite an economic slowdown in several countries of the region such as India, the increasing public healthcare programs including the increasing private wealth are further expected to propel the healthcare spending of Asia-Pacific by an annual average of 6.6% from 2015 to 2019. Asia-Pacific is growing at a modest rate in the market due to various factors such as rising healthcare spending, improving infrastructure, and rising standards of living. China, India, Japan, Australia, Korea, and Taiwan are the key countries growing at a significant rate in the Asia-Pacific Graves’ diseases market.
Research Methodology:
The market study of the Asia-Pacific Graves’ disease market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Asia-Pacific Graves’ Disease Market Research and Analysis by Diagnosis
2. Asia-Pacific Graves’ Disease Market Research and Analysis by Treatment
The Report Covers:
- Comprehensive Research Methodology of the Asia-Pacific Graves’ disease market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Asia-Pacific Graves’ disease market.
- Insights about market determinants which are stimulating the Asia-Pacific Graves’ disease market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories Inc.
- Allergan PLC
- Eli Lilly and Co.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Macleods Pharmaceuticals Ltd.
- Merck & Co. Inc.
- Mylan NV
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
